Oncology: Medical and Market Assessment for Surufatinib

The client from international company asked to translate complex medical information about the Surufatinib product launch into understandable and accessible formats.

In the framework of this project, I conducted interviews with key opinion leaders in Oncology field, as well as developed a collaboration with patient registries and analyzed the recent regulatory documents upon medical technology landscape in neuroendocrine tumors field.

As a result, I summarized the data in the attached presentation in PDF format, ensuring that it covers every field on the Surufatinib approval process, including:

1. Neuroendoctine Tumors (NET) Patient registries in market X
2. Patient flow in market X : current & prognosis
3. Diagnostic routes for patients with NET in market X
4. Treatment distribution in G1-G2 NET patients in market X: National vs USA guidelines
5. Patient flow with NET for Surufatinib Tx in market X
6. Current and future local competitive landscape
7. Centers of Excellence and KOL engagement
8. HTA aspects for reimbursement coverage
9. Regulatory pathway and time-to-market
10. Medical activities for market access #pitchdeck #pdf